Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
DNTH
DNTH
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DNTH News
Dianthus Therapeutics FDA Approves Clinical Changes for Claseprubart
4d ago
seekingalpha
5AM Venture Management Fully Exits Dianthus Therapeutics
Mar 18 2026
Fool
Dianthus Therapeutics Hits Early 'Go' in CAPTIVATE Phase 3 CIDP Trial
Mar 15 2026
Yahoo Finance
Dianthus Therapeutics (DNTH.US) Director Plans to Sell $10.55 Million in Common Stock via Form 144
Mar 12 2026
moomoo
Dianthus Therapeutics Prices $625 Million Upsized Public Offering
Mar 11 2026
NASDAQ.COM
Dianthus Therapeutics Prices Upsized $625 Million Public Offering
Mar 11 2026
seekingalpha
Wall Street Analysts Adjust Ratings
Mar 10 2026
Benzinga
Wall Street Analysts Adjust Ratings
Mar 10 2026
Benzinga
Dianthus Therapeutics Launches $400 Million Public Offering
Mar 09 2026
seekingalpha
Liquidia and Dianthus See Active Options Trading
Mar 09 2026
NASDAQ.COM
Dianthus Therapeutics Early Decision Boosts Stock Surge
Mar 09 2026
stocktwits
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
Mar 09 2026
Benzinga
Dianthus Achieves Key Milestones in CIDP Trial
Mar 09 2026
Benzinga
Dianthus Therapeutics Reports Q4 Earnings Miss
Mar 09 2026
seekingalpha
Dianthus Therapeutics Reports Interim Results from CAPTIVATE Trial
Mar 09 2026
NASDAQ.COM
Dianthus Announces CAPTIVATE Trial Interim Results Conference Call
Mar 08 2026
Newsfilter
Show More News
